TickerTalks
Browse all tickers →
TickerTalks›$ABEO
ABABEO

Abeona Therapeutics Inc.

$ABEO·$422M·Biotechnology·Healthcare
$5.92-2.0%YTD+19.7%1Y-12.5%
Mentions · last 7 days
2026-08-20: 3 posts2026-08-21: 2 posts2026-08-22: 3 posts2026-08-23: 2 posts290%
Price updated 1d ago·X counts updated 6d ago
ABABEO
$ABEOAbeona Therapeutics Inc.
$5.92-1.99%29 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $ABEO, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-08-28

Falling on heavy selling — points lower unless it turns around.

ZEVASKYN launched, but manufacturing yield problems and a securities-fraud investigation have taken the story apart.

Abeona Therapeutics is down about 12% over twelve months despite having done the thing biotechs exist to do — get a product approved and launched. ZEVASKYN is commercial. The reason the stock has not been rewarded is that the launch has run into manufacturing yield issues, and for an autologous cell therapy, manufacturing is not a back-office problem: it is the product. Yield problems directly cap how many patients can be treated and therefore what the revenue ramp can look like, regardless of demand.

Compounding that, Pomerantz has opened a class-action investigation. Plaintiff-firm investigations are common enough after any drawdown that they are weak evidence on their own, but in combination with a specific operational shortfall against launch expectations, it points at a gap between what was communicated and what was delivered.

The honest read is that this is a company with a real approved product and a real execution problem, and the market is pricing the execution problem as the binding constraint. That is a solvable issue in principle — manufacturing scale-up problems get fixed — but the timeline and the cost of fixing them are the open questions, and neither is knowable from outside.

X sentiment carries little conviction on this name and does not add much beyond the headlines.

Differs from X sentimentX chatter is thin and does not engage with the manufacturing yield issue, which is the fact that actually determines the revenue ramp.

What to watch: Manufacturing yield and patient-treated counts on the next call — the direct measure of whether the constraint is easing. Developments in the Pomerantz investigation.

On the calendar: Next quarterly earnings report

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment6 posts analyzed · as of 2026-08-20

Abeona Therapeutics posters are split on ZEVASKYN. Q2 revenue rose 31% sequentially to $11.4M (5 treated, 4 recognized), but ABEO was down -17% premarket because one batch fell under the sheet threshold for revenue recognition (a first-time low-yield batch, currently 9 sheets per lot on average) — 'not falling demand.' Only three ZEVASKYN treatments in Q3 to date is well below expectations. Manufacturing yields emerge as the red flag. Mixed with a bearish tilt.

Read the AI verdict + X sentiment for $ABEO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage gene and cell therapy biotech targeting rare genetic skin and metabolic diseases with next-gen delivery platforms.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ABEO.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
5.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-50.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-6.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-20.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
29.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
41.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
51.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.35$-0.23-51.1%
Q1 2026May 13, 2026$-0.30$-0.33+9.1%
Q4 2025Mar 17, 2026$-0.34$-0.35+2.9%
Q3 2025Nov 12, 2025$-0.10$-0.27+63.0%
Next earningsWed, Nov 11·consensus EPS $-0.17

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$8.7M—59.1%-264%$-0.30$-20.7M
Q4 FY25$5.4M—47.7%-423%$-0.39$-19.1M
Q3 FY25$0———$-0.10$-23.7M
Q2 FY25$400K—75.0%-5698%$2.07$-21.7M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$66.3M$50.2M – $83.9M-$0.75-$1.03 – -$0.435
FY27$139.6M$101.9M – $216.7M-$0.07-$0.35 – $0.435
FY28$211.2M$158.4M – $252.4M$0.40-$0.46 – $0.994
FY29$290.3M$213.0M – $401.2M$1.51$0.99 – $2.262
FY30$349.9M$256.7M – $483.6M$1.97$1.29 – $2.942

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.53%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-7.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 36.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.345-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 21Vazzano Joseph WalterCFO1.5K sh$10KSellJul 9Vazzano Joseph WalterCFO24.9K sh$173KSellJul 9Vishwas SeshadriCEO68.0K sh$473KSellJul 9Brendan M. O'malleySVP, Chief Legal Officer12.1K sh$84KSellJul 9Madhav VasanthavadaChief Commercial Officer12.6K sh$88KSellJun 30Leila AllandDirector11.0K sh$65KSellJun 15Silverstein Christine BerniDirector18.2K sh$104KSellJun 9Vishwas SeshadriCEO31.9K sh$169KSellJun 9Brendan M. O'malleySVP, Chief Legal Officer6.3K sh$33KSellJun 9Vazzano Joseph WalterCFO39.1K sh$209K
1–10 of 20
+ 3 other (1 other · 1 gift · 1 award) in window

See when $ABEO insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change
8-KPress release / Reg FDJun 108-K — Item 7.01: Press release / Reg FD
3New insider — initial holdingsApr 73
8-KOfficer or director changeApr 78-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KCharter amendmentMar 208-K — Item 5.03: Charter amendment
+ 20 other (7 13Gs · 3 earnings 8-Ks · 2 10-Qs · 2 routine 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOprnewswire.com·2d agoAbeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunityseekingalpha.com·17d agoAbeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcriptseekingalpha.com·17d agoAbeona Therapeutics Q2 Earnings Call Highlightsmarketbeat.com·17d agoAbeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Updateglobenewswire.com·17d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $ABEO on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport